APA (7th ed.) Citation

FL, D., S, B., G, B., S, E., E, D., MR, M., . . . S, T. (2010). Plasma matrix metalloproteinase-9 better predicts outcome than N-terminal protype-B natriuretic peptide in patients with systolic heart failure and a high prevalence of coronary artery disease. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 64(5), 339. https://doi.org/10.1016/j.biopha.2009.09.008

Chicago Style (17th ed.) Citation

FL, Dini, Buralli S, Bajraktari G, Elezi S, Duranti E, Metelli MR, Carpi A, and Taddei S. "Plasma Matrix Metalloproteinase-9 Better Predicts Outcome than N-terminal Protype-B Natriuretic Peptide in Patients with Systolic Heart Failure and a High Prevalence of Coronary Artery Disease." Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie 64, no. 5 (2010): 339. https://doi.org/10.1016/j.biopha.2009.09.008.

MLA (9th ed.) Citation

FL, Dini, et al. "Plasma Matrix Metalloproteinase-9 Better Predicts Outcome than N-terminal Protype-B Natriuretic Peptide in Patients with Systolic Heart Failure and a High Prevalence of Coronary Artery Disease." Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, vol. 64, no. 5, 2010, p. 339, https://doi.org/10.1016/j.biopha.2009.09.008.